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ABSTRACT
Objective: The purpose of this study was to compare the clinical efficacy and safety of trospecto-
mycin sulfate with that of clindamycin phosphate, both with aztreonam, for the treatment of ob-
stetric and gynecologic infections.
Methods: In a double-blind, multicenter, prospective randomized study, 579 patients with either
endometritis following cesarean delivery or pelvic cellulitis following hysterectomy were enrolled
and received medication. Administered was either trospectomycin sulfate 500 mg IV every 8 h or
clindamycin phosphate 900 mg IV every 8 h in a 1:1 randomization ratio. Both groups of patients
received aztreonam 1 g IV every 8 h. The patients were followed for clinical responses and side
effects.
Results: The cure rate for the trospectomycin sulfate arm was 91.8% and for clindamycin phos-
phate arm it was 88.4% (P 0.218). The adverse events were similar in both groups.
Conclusions: Trospectomycin was as effective as clindamycin, when both were combined with
aztreonam, in treatment of obstetric and gynecologic infections. Infect. Dis. Obstet. Gynecol. 5:
280-285, 1997. (C) 1998 Wiley-Liss, Inc.
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emale pelvic infections that occur following ob-
stetric and gynecologic procedures are often
polymicrobial, involving both aerobic and anaero-
bic bacteria. 1-4 Isolated from these patients are
bacteria which are similar to those isolated from the
vagina and endocervix of healthy women. This ob-
servation implies that infections following obstetric
and gynecologic procedures are frequently from as-
cent of endogenous bacteria of the vaginal flora.
A major cause of postpartum morbidity and mor-
tality is endometritis. This is especially true in pa-
tients who have undergone cesarean delivery,s,6
The incidence of endometritis following cesarean
delivery ranges from 8 to 55%,6-8 despite the use of
perioperative prophylactic antibiotics.
Hysterectomy is one of the most common sur-
gical procedures in the United States. Prior to
widespread use of antimicrobial prophylaxis,9 the
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incidence of infection following hysterectomy was
60% and included cuff cellulitis and pelvic celluli-
tis. The latter is observed during the immediate
postoperative period, while cuff cellulitis often
presents after discharge from the hospital.
The commonly isolated aerobic organisms in in-
fections that occur after obstetric and gynecologic
procedures are gram-negative facultative bacteria,
especially Escherichia coli, hemolytic and non-
hemolytic streptococcus, Klebsiella pneumoniae, and
Proteus spp. The anaerobic bacteria that are fre-
quently isolated include Peptostreptococcus, Peptococ-
cus, and Bacteroides spp.
Parenteral antibiotic therapy is the mainstay of
therapy of pelvic infections following obstetric and
gynecologic procedures. Initial therapy for such in-
fection consists of a broad-spectrum antibiotic cov-
erage with activity against most of the Bacteroides
spp., as well as gram-positive and gram-negative
aerobes. In many clinical trials, the combination
therapy with clindamycin and gentamicin has been
considered the standard for comparison of the
treatment of genital tract infections.
The incidence of nausea, vomiting, and diarrhea
with clindamycin therapy ranges from 2 to 6%.1
The more serious gastrointestinal problem, pseu-
domembranous colitis (PMC), may be greater with
clindamycin than with other antibiotics. The
ranges are highly variable, with a reasonable esti-
mate being in 10,000.1
Trospectomycin sulfate is a novel broad-
spectrum aminocyclitol antibiotic with activity
against a majority of aerobes, anaerobes, Neisseria
gonorrhoeae, and Chlamydia trachomatis. z-14 Tro-
spectomycin binds to the 30-s ribosomal subunit of
bacteria, thus inhibiting protein synthesis. The po-
tential utility of this antibiotic is in the treatment of
gonorrhea, gynecologic/pelvic infections, including
pelvic inflammatory disease and endometritis,
pneumonia, and intra-abdominal infections caused
by anaerobes. In in vitro studies, trospectomycin
was shown to have achievable minimal inhibitory
concentrations (MICs) against a broad spectrum of
pathogenic species including Streptococcus, Hae-
mophilus, Neisseria, Peptococcus, Peptostreptococcus,
Bacteroides, Chlamydia, and Alycoplasma. Reduced
activity has been observed against Enterobacteriace-
ae. Trospectomycin is not active against Pseudomo-
has spp.
Clindamycin has long been one of the antibiot-
ics of choice in the treatment of obstetric and gy-
necologic infections. Therefore, it is possible that
resistant strains of pathogens may emerge. Because
of the adverse effects and the possibility of the
development of drug-resistant organisms, there is a
need for a new antibiotic with a wide range of aero-
bic and anaerobic coverage.
The objectives of the study were to compare the
safety and efficacy of trospectomycin sulfate with
aztreonam vs. clindamycin phosphate with aztreo-
nam in the treatment of infection following obstet-
ric and gynecologic procedures.
SUBJECTS AND METHODS
Patients
The patients eligible for enrollment were hospital-
ized women, 16 years of age or older, with a pre-
sumptive diagnosis of pelvic cellulitis following
hysterectomy or endometritis following cesarean
delivery. The diagnosis of.pelvic cellulitis was
based on abdominal tenderness with or without re-
bound tenderness, parametrial tenderness on vagi-
nal examination, and oral temperature >38.3C af-
ter the first 24-h period. The admission white cell
count needed to be over 10,000/ram3. For a diag-
nosis of endometritis, in addition to elevated tem-
perature and white cell count requirements, fundal
tenderness on abdominal examination along with
parametrial tenderness and purulent lochia on vagi-
nal examination needed to be present. Patients
with symptoms suggesting other foci of infection,
e.g., urinary tract or pulmonary system, were ex-
cluded from the study, as were patients who had
received non-prophylactic antibiotics, within 14
days of recruitment in the study. Patients were also
excluded if they had a history of hypersensitivity to
trospectomycin, clindamycin, aztreonam, or spec-
tinomycin, breast-feeding, myasthenia gravis, liver
or kidney dysfunction, antibiotic-associated colitis,
immunologic deficiency, and neoplastic diseases.
Study Design
This was a phase III, comparative, double-blind,
randomized study of trospectomycin sulfate and
clindamycin phosphate, both with aztreonam, in
the treatment of pelvic infection following obstet-
ric and gynecologic procedures. The institutional
review boards of the 18 participating centers ap-
proved the clinical protocol for this study. The cen-
ters were chosen from geographic areas so as to
obtain a heterogeneous group of patients. The
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pharmaceutical sponsor provided a simple com-
puter-generated randomization table for each site.
A 1:1 allocation of screened patients to trospecto-
mycin vs. clindamycin was used.
After each patient had given written informed
consent, a physical examination was performed and
the following laboratory studies were conducted:
urinalysis, complete blood count (CBC) with dif-
ferential, prothrombin time, direct Coomb’s test,
alanine aminotransferase, aspartate aminotransfer-
ase, lactic dehydrogenase, alkaline phosphatase, to-
tal bilirubin, blood urea nitrogen, and serum creat-
inine. Cultures were obtained from the urine,
uterus, or vaginal cuff, and, if indicated, blood,
prior to treatment. The indications for blood cul-
ture were left to the discretion of each individual
investigator. Uterine cultures were obtained by
transcervical protected brush or endometrial aspi-
ration curette. Cultures were obtained for faculta-
rive aerobes and anaerobes. Standard culture media
and culture techniques were utilized for aerobic
and anaerobic bacteria. Organism susceptibility
was based on either MIC or inhibition zone. If both
were recorded, MIC was used. The susceptibility
breakpoints for all antibiotics were established be-
fore the start of the study. An MIC for trospecto-
mycin was established at <16 pg/ml, for clindamy-
cin at <1.6 pg/ml, and for aztreonam at <8 pg/ml.
An inhibitory zone diameter for trospectomycin
and clindamycin was established at >17 mm and
for aztreonam at >22 mm.
The treatment regimen consisted of IV therapy
with 500 mg trospectomycin or 900 mg clindamycin
as a 30-min infusion every 8 h. Both groups of pa-
tients received 1 g IV aztreonam every 8 h. The
study medication was continued for 24 h following
the resolution of the signs and symptoms of pelvic
infection. No discharge antibiotics were given to
either group.
Patient Evaluation
Over the course of treatment, the patients were
observed regarding their clinical status and poten-
tial adverse reactions. Specific questions were
asked daily regarding any local discomfort at the IV
site. Other factors included oral temperature evalu-
ations every 4-6 h. The blood culture was repeated
daily for a patient with a positive culture before
treatment until it became negative. All clinical
laboratory tests were repeated every 3 days while
the patient was hospitalized, and again on the day
of discharge.
The disappearance of all signs and symptoms of
endometritis or pelvic cellulitis defined a satisfac-
tory clinical response to treatment. A clinical failure
was defined as a temperature of >38C on one or
more occasions in a patient who had received an-
tibiotics for a minimum of 48 h, along with persis-
tence or worsening of the signs and symptoms of
endometritis or pelvic cellulitis that required
changing the antimicrobial agents.
Statistical Evaluation
For continuous variables, e.g., age, the treatment
differences were tested using a one-way analysis of
variance (ANOVA) model, with treatment as the
factor. Categorical variables, e.g., race, and the pro-
portion of patients reporting at least one medical
event during the study were compared between
groups using the Pearson chi-square test for homo-
geneity of distribution. The number of days in the
hospital until discharge was investigated using a
two-way ANOVA. The evaluability rate, stratified
by clinical site, was compared between treatment
groups using the Cochran-Mantel-Haenszel test.
All statistical tests were two-sided tests. The re-
suits were reported as statistically significant ifP <
0.05 was obtained.
RESULTS
Patients
Among the participating institutions, a total of 579
patients were enrolled: 292 in the trospectomycin
group and 287 in the clindamycin group. All 579
patients received study medication and were thus
evaluable for safety. The two groups were compa-
rable with regard to age, weight, height, race, and
initial temperature (Table 1). Forty-nine patients
from the trospectomycin group and 45 from the
clindamycin group were excluded for the efficacy
evaluation. The reasons for exclusion included pro-
tocol violations as well as use of concomitant anti-
biotic, and other foci of infection. In fact, patients
receiving more than one dose of preoperative anti-
biotics constituted the most common reason for ex-
clusion, followed by normal white cell count at the
time of admission in the study. The total numbers
of patients excluded were 28 in the trospectomycin
group and 25 in the clindamycin group for the
above reason. There were 4 patients in the tro-
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TABLE I. Patient characteristics: all patients
Trospectomycin Clindamycin
Variable (n 292) (n 287)
Mean age + SD (years) 26.2 + 8.91 25.8 + 8.52
Weight + SD (kg) 76.7 + 20.46 77.8 + 17.95
Height +/- SD (cm) 160.4 +/- 7.03 160.8 +/- 7.69
Race (%)
Black 51.4 48.3
White 17.5 22.3
Hispanic 28. 28.2
Oriental 1.4 0.7
Others 1.6 0.5
Initial temperature +/- SD (C) 38.5 +/- 0.64 38.5 +/- 0.59
spectomycin group and 3 in the clindamycin group
who were excluded because of their exposure to
concomitant antibiotics. The concomitant use of
antibiotics was primarily because of positive test for
syphilis or chlamydia. Furthermore, 10 patients in
each of the above groups were excluded from the
study because of other foci of infection, i.e., pul-
monary, ocular, or urinary tract. Seven patients in
each of these two groups requested to be with-
drawn from the study. The exclusion rate was not
statistically different between the treatment
groups. Evaluable patients and indications for in-
clusion are listed in Table 2.
Outcome
The overall mean duration of the study drug
therapy was similar in both groups, i.e., 4.1 ___
1.11
days. The overall success rate for the trospectomy-
cin group was 223/243 (91.8%) compared with 214/
242 (88.4%) for the clindamycin group (P 0.218;
Table 3).
There was a higher proportion of pretreatment
isolates resistant to clindamycin than to trospecto-
mycin. Among all the isolates from all treated
patients that were tested for susceptibility to tro-
spectomycin, the number of isolates resistant to
trospectomycin was 42/1,050 (4%). In comparison,
among all the isolates from all treated patients that
were tested for susceptibility to clindamycin, the
number of isolates resistant to clindamycin was
379/809 (47%). The most common organism iso-
lated among the treated patients was Enterococcus.
Of the 204 Enterococcus isolates that were tested for
susceptibility to trospectomycin, two were resistant
to trospectomycin. On the other hand, of the 185
Enterococcus isolates tested for susceptibility to clin-
damycin, 158 were resistant to clindamycin. The
TABLE 2. Indications: evaluable patients
Indication Trospectomycin Clindamycin
Post-cesarean endometritis 200 202
Post-hysterectomy pelvic
cellulitis 43 40
Total 243 242
sensitivity for gram-positive aerobes, other than
Enterococcus spp., was similar for trospectomycin
and clindamycin. All gram-negative aerobes were
resistant to clindamycin, while sensitivity to tro-
spectomycin ranged from 0% for Pseudomonas to
100% for Acinetobacter. The sensitivity of Escherichia
coli to trospectomycin was 93%. The sensitivity of
Bacteroides spp. was 82% and 79% for trospectomy-
cin and clindamycin, and for Peptostreptococcus it
was 100% and 97%, respectively.
The overall frequency of adverse events was not
significantly different between the two groups;
28% of patients in the trospectomycin group had
one or more medical events compared with 28% of
those treated with clindamycin. Medical events re-
lating to the gastrointestinal system were the most
frequent, with 24/292 (8%) patient complaints for
trospectomycin and 29/287 (10%) for clindamycin.
Of the 24 patients who reported gastrointestinal
events in the trospectomycin group, the most com-
monly reported complaint was diarrhea (7 events)
and for 29 patients in the clindamycin group, diar-
rhea was again the most common complaint (13
events).
Failures
Twenty failures were reported in the trospectomy-
cin group and 28 in the clindamycin group. All of
these patients had received study medications for a
minimum of 48 h. The 18 patients in the trospec-
tomycin group who continued to have fever spikes
and evidence of pelvic infection were deemed
treatment failures. They subsequently responded
to alternate antibiotic regimens, which included
various combinations of clindamycin, gentamicin,
ampicillin, cephalexin, doxycycline, and amoxicil-
lin/calvulanic acid. One patient developed septic
thrombophlebitis and recovered after heparin
therapy. One patient was found to have cytomeg-
alovirus infection and recovered spontaneously af-
ter failing study medication and combination of
ampicllin, clindamycin, and gentamicin. In the
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TABLE 3. Clinical success rate
Trospectomycin Clindamycin
N % N % P
SUCCESS
Total 223/243
Post-cesarean endometritis 186/200
Post-hysterectomy pelvic cellulitis 37/43
Failure
Total 20/243
Post-cesarean endometritis 14/200
Post-hysterectomy pelvic cellulitis 6/43
91.8 214/242 88.4 0.218
93.0 181/202 89.6 NS
86.0 33/40 82.5 NS
8.2 28/242 II .6 NS
7.0 21/202 10.4 NS
14.0 7/40 17.5 NS
clindamycin group, 25 patients were deemed treat-
ment failures and were subsequently treated with
different antibiotics. Three patients developed
wound infection and responded to local treatment.
DISCUSSION
Clindamycin, in combination with gentamicin, has
long been considered the gold standard in treat-
ment of obstetrical and gynecologic infection. Clin-
damycin is bacteriostatic, and apart from its excel-
lent activity against anaerobic organisms, has very
good activity against gram-positive aerobic organ-
isms, including nafcillin-sensitive Staphylococcus au-
reus, and non-enterococcal streptococcus. However,
the disadvantage of clindamycin is its poor activity
against gram-negative aerobes. In addition, the in-
cidence of PMC may be greater with clindamycin
than with other antibiotics.
Trospectomycin is a novel broad-spectrum ami-
nocyclitol antibiotic with a broad spectrum of ac-
tivity. It is a 6’ propyl analog of spectinomycin.
Trospectomycin has been shown to be effective
against most aerobes, anaerobes, Neisseria gonor-
rhoeae, Chlamydia trachomatis, and Ureaplasma and
Mycoplasma spp. In a previous open-label phase II
study of trospectomycin by the sponsor in patients
with chlamydia pelvic infection requiring hospital-
ization, 93% of patients had negative culture at the
end of the therapy. In another previous phase III
study by the sponsor to treat post-surgical gyneco-
logic infection, trospectomycin was effective in
92% of patients while clindamycin was effective in
87% of patients.
Aztreonam is a first member of a class of antibi-
otics called monolactams. Aztreonam is a totally
synthetic bactericidal antibiotic with activity
against a wide spectrum of gram-negative aerobic
pathogens. Activity of aztreonam against gram-
negative aerobic pathogens is comparable to that of
gentamicin. The sponsor of this study elected to
use aztreonam.
We have shown that pelvic infection following
obstetric and gynecologic procedures can be
treated effectively with trospectomycin and aztreo-
nam therapy, achieving a clinical success rate of
91.8%. The success rate for clindamycin and az-
treonam was 88.4%. The difference in the success
rate was not statistically significant. Trospectomy-
cin was shown to be effective against many gram-
negative aerobes, while clindamycin was resistant
to all gram-negative aerobes. The addition of az-
treonam in both groups, an antibiotic known to be
effective against gram-negative aerobes, probably
was the reason for similar efficacy in the two
groups.
Even though most of the enterococci were re-
sistant to clindamycin, the clinical cure rate was
similar in two groups. This may be because entero-
coccus may not be the sole pathogenic organism,
especially in light of the polymicrobial nature of
female pelvic infections.
In summary, trospectomycin in combination
with aztreonam gave a similar success rate as clin-
damycin and aztreonam combination in treatment
of obstetric and gynecologic infections. However,
broad-spectrum activity of trospectomycin warrants
consideration of its use as a single agent therapy in
pelvic infection following obstetric and gynecologic
infection.
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